Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity
96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility.
New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model.
Biophytis announces new preclinical results for its investigational drug BIO101. These results were presented for the first time last week at the 15th International Conference on Frailty and Sarcopenia Research in Toulouse.
Key findings on BIO101 in obesity include:
In this newly reported preclinical study BIO101, in combination with GLP-1, protected muscle strength and mobility in an animal model: In this preclinical study conducted on diet-induced obese mice, four weeks combination treatment of BIO101 with a GLP-1 receptor agonist significantly improved animal mobility (endurance) and grip strength when compared to untreated groups. Notably, the combination of drugs compensates for muscle contractility alterations induced by GLP-1 in a twitch test performed on an isolated muscle.
BIO101 showed beneficial effects on muscle strength and mobility in humans in previous early-phase clinical trials: Furthermore, in the SARA-INT (Phase 2) study on sarcopenic obesity and Quinolia (Phase 1-2) study on obesity, the BIO101-treated obese patient cohorts were observed to have improved musclestrength and mobility compared to placebo cohorts.
Addressing a Global Health Crisis
Obesity affects nearly one billion people worldwide and is linked to severe comorbidities, specifically including that 96% of patients with obesity report experiencing a specific decline in muscle strength.
Stanislas Veillet, CEO of Biophytis, stated: “Despite the progress made with the development of GLP-1 treatments for obesity, no therapy currently exists to restore muscle strength and mobility in patients with obesity. Biophytis is pioneering research to address this critical unmet medical need. We are eager to advance the development of BIO101 in combination with GLP-1 within our Phase 2 OBA clinical trial.”
The full presentation is available on our website.